- Home
- MDGL
as 12-20-2024 4:00pm EST
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | WEST CONSHOHOCKEN |
| Market Cap: | 7.4B | IPO Year: | N/A |
| Target Price: | $347.33 | AVG Volume (30 days): | 355.8K |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -25.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $168.25 - $368.29 | Next Earning Date: | 10-31-2024 |
| Revenue: | $76,813,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 194.49% |
Stock Insider Trading Activity of Madrigal Pharmaceuticals Inc. (MDGL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| CRAVES FRED B | MDGL | Director | Dec 3 '24 | Sell | $315.56 | 3,600 | $1,135,121.70 | 11,520 | |
| CRAVES FRED B | MDGL | Director | Nov 25 '24 | Sell | $350.40 | 3,400 | $1,191,028.02 | 11,520 | |
| Huntsman Carole | MDGL | Chief Commercial Officer | Nov 21 '24 | Sell | $316.92 | 688 | $218,040.96 | 10,785 | |
| Levy Richard S | MDGL | Director | Nov 7 '24 | Sell | $350.00 | 5,000 | $1,750,000.00 | 11,012 | |
| Levy Richard S | MDGL | Director | Nov 1 '24 | Sell | $301.96 | 5,000 | $1,504,703.41 | 11,012 |
Latest Madrigal Pharmaceuticals Inc. News
MDGL Breaking Stock News: Dive into MDGL Ticker-Specific Updates for Smart Investing
Simply Wall St.
4 days ago
Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Profit Outlook
TipRanks
16 days ago
Madrigal Pharmaceuticals price target raised to $427 from $415 at JMP Securities
MT Newswires
17 days ago
Madrigal Pharmaceuticals Insider Sold Shares Worth $1,135,122, According to a Recent SEC Filing
Motley Fool
a month ago
3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move
Zacks
a month ago
Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy?
Insider Monkey
a month ago
Why Is Madrigal Pharmaceuticals, Inc. (MDGL) Among the Worst Performing Biotech Stocks in 2024?
Pharma Voice
a month ago
The first MASH drug could open the door for others — including GLP-1s
GuruFocus.com
a month ago
John Paulson's Strategic Moves in Q3 2024: A Focus on Anglogold Ashanti PLC
Compare MDGL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MDGL Madrigal Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.